NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
VEPESID (etoposide) by Engine Biosciences is topoisomerase inhibitors [moa]. Approved for lung cancer, small cell lung cancer, non-small cell lung cancer and 1 more indications. First approved in 1983.
Drug data last refreshed 18h ago
Mechanism of Action
Topoisomerase Inhibitors
Worked on VEPESID at Engine Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.